Vtesse Pharma

Developed VTS-270 to treat patients with Niemann-Pick Disease Type C.

Launch date

2014

Employees

Market cap

Enterprise valuation

Gaithersburg Maryland (HQ)

Date	Investors	Amount	Round
-	Lundbeckfonden	N/A	-
Jan 2014	Lundbeckfonden Ventures New Enterprise Associates Bay City Capital Pfizer Alexandria Venture Investments	$25.0m	Series A
Jan 2015	Lundbeckfonden Ventures New Enterprise Associates Bay City Capital	$25.0m	Series A
Jul 2016	Lundbeckfonden Ventures New Enterprise Associates Bay City Capital Pfizer Alexandria Venture Investments	$17.0m	Series A
Apr 2017	Sucampo Pharmaceuticals	N/A	Acquisition
Total Funding		CAD91.4m

Tech stackLearn more about the technologies and tools that this company uses.

Recent News about Vtesse Pharma